Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 17;10(1):22217.
doi: 10.1038/s41598-020-78809-x.

Epigenetic differences at the HTR2A locus in progressive multiple sclerosis patients

Affiliations

Epigenetic differences at the HTR2A locus in progressive multiple sclerosis patients

Vicki E Maltby et al. Sci Rep. .

Abstract

The pathology of progressive multiple sclerosis (MS) is poorly understood. We have previously assessed DNA methylation in the CD4+ T cells of relapsing-remitting (RR) MS patients compared to healthy controls and identified differentially methylated regions (DMRs) in HLA-DRB1 and RNF39. This study aimed to investigate the DNA methylation profiles of the CD4+ T cells of progressive MS patients. DNA methylation was measured in two separate case/control cohorts using the Illumina 450K/EPIC arrays and data was analysed with the Chip Analysis Methylation Pipeline (ChAMP). Single nucleotide polymorphisms (SNPs) were assessed using the Illumina Human OmniExpress24 arrays and analysed using PLINK. Expression was assessed using the Illumina HT12 array and analysed in R using a combination of Limma and Illuminaio. We identified three DMRs at HTR2A, SLC17A9 and HDAC4 that were consistent across both cohorts. The DMR at HTR2A is located within the bounds of a haplotype block; however, the DMR remained significant after accounting for SNPs in the region. No expression changes were detected in any DMRs. HTR2A is differentially methylated in progressive MS independent of genotype. This differential methylation is not evident in RRMS, making it a potential biomarker of progressive disease.

PubMed Disclaimer

Conflict of interest statement

VEM: has received honoraria for presentations from Biogen and Merck Serono. HB: serves on steering committees and scientific advisory boards for Merck, Biogen, Novartis and Roche. Has received conference travel support from Merck. Institution has received honoraria for speaker engagements for Merck, Biogen, Roche and Novartis. Institution has received research support from Biogen, Roche, Merck, Novartis, NHMRC, MRFF, Trish Foundation, MSRA. Receives personal compensation for serving on the Brain health initiative Steering Committee. JLS’s institution receives non-directed funding as well as honoraria for presentations and membership on advisory boards from Sanofi Aventis, Biogen Idec, Bayer Health Care, Merck Serono, Teva and Novartis Australia. The other authors declare no competing interests.

Figures

Figure 1
Figure 1
HTR2A DMR plot. The mean beta value at the eight HTR2A CpG sites for controls (solid red line) and SPMS patients (dotted blue line) located within the transcription start site. Error bars show standard error of the mean.
Figure 2
Figure 2
Haplotype block at HTR2A. Haploview chart showing the 7 haplotype blocks at HTR2A. Blocks are indicated by a bold black outline. SNPs contained within the block are in bold and the length of the block is indicated (in base pairs) in parentheses. This plot provides information on both the r2 and D′ values for better clarification of any linkage disequilibrium. The number within each diamond represents the r2 value between each diagonally corresponding SNP pairs and the colour of each diamond represents the strength/value of D′ (white to bright red/0 < 100).
Figure 3
Figure 3
HTR2A mQTL. Mean delta beta values at cp09798090 for SNP rs6313 in either the non-risk allele (T/T) or risk allele (C/C or T/C). Healthy controls (HC) are shown in blue, SPMS are shown in read. Error bars are standard error of the mean.

References

    1. Segal BM. Stage-specific immune dysregulation in multiple sclerosis. J. Interferon Cytokine Res. 2014;34:633–640. doi: 10.1089/jir.2014.0025. - DOI - PMC - PubMed
    1. Broux B, Stinissen P, Hellings N. Which immune cells matter? The immunopathogenesis of multiple sclerosis. Crit. Rev. Immunol. 2013;33:283–306. doi: 10.1615/CritRevImmunol.2013007453. - DOI - PubMed
    1. Palmer AJ, Colman S, O'Leary B, Taylor BV, Simmons RD. The economic impact of multiple sclerosis in Australia in 2010. Mult. Scler. 2013;19:1640–1646. doi: 10.1177/1352458513488230. - DOI - PubMed
    1. Zhu H, et al. A genome-wide methylation study of severe vitamin D deficiency in African American adolescents. J. Pediatr. 2013;162:1004–1009. doi: 10.1016/j.jpeds.2012.10.059. - DOI - PMC - PubMed
    1. Wan ES, et al. Cigarette smoking behaviors and time since quitting are associated with differential DNA methylation across the human genome. Hum. Mol. Genet. 2012;21:3073–3082. doi: 10.1093/hmg/dds135. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

Grants and funding